235,50 €*
Versandkostenfrei per Post / DHL
Aktuell nicht verfügbar
Oligonucleotide-based drugs, in particular antisense oligonucleotides, are part of a growing number of pharmaceutical and biotech programs progressing to treat a wide range of indications including cancer, cardiovascular, neurodegenerative, neuromuscular, and respiratory diseases, as well as other severe and rare diseases. Reviewing fundamentals and offering guidelines for drug discovery and development, this book is a practical guide covering all key aspects of this increasingly popular area of pharmacology and biotech and pharma research, from the basic science behind antisense oligonucleotides chemistry, toxicology, manufacturing, to safety assessments, the design of therapeutic protocols, to clinical experience.
Antisense oligonucleotides are single strands of DNA or RNA that are complementary to a chosen sequence. While the idea of antisense oligonucleotides to target single genes dates back to the 1970's, most advances have taken place in recent years. The increasing number of antisense oligonucleotide programs in clinical development is a testament to the progress and understanding of pharmacologic, pharmacokinetic, and toxicologic properties as well as improvement in the delivery of oligonucleotides. This valuable book reviews the fundamentals of oligonucleotides, with a focus on antisense oligonucleotide drugs, and reports on the latest research underway worldwide.
* Helps readers understand antisense molecules and their targets, biochemistry, and toxicity mechanisms, roles in disease, and applications for safety and therapeutics
* Examines the principles, practices, and tools for scientists in both pre-clinical and clinical settings and how to apply them to antisense oligonucleotides
* Provides guidelines for scientists in drug design and discovery to help improve efficiency, assessment, and the success of drug candidates
* Includes interdisciplinary perspectives, from academia, industry, regulatory and from the fields of pharmacology, toxicology, biology, and medicinal chemistry
Oligonucleotide-Based Drugs and Therapeutics belongs on the reference shelves of chemists, pharmaceutical scientists, chemical biologists, toxicologists and other scientists working in the pharmaceutical and biotechnology industries. It will also be a valuable resource for regulatory specialists and safety assessment professionals and an important reference for academic researchers and post-graduates interested in therapeutics, antisense therapy, and oligonucleotides.
Oligonucleotide-based drugs, in particular antisense oligonucleotides, are part of a growing number of pharmaceutical and biotech programs progressing to treat a wide range of indications including cancer, cardiovascular, neurodegenerative, neuromuscular, and respiratory diseases, as well as other severe and rare diseases. Reviewing fundamentals and offering guidelines for drug discovery and development, this book is a practical guide covering all key aspects of this increasingly popular area of pharmacology and biotech and pharma research, from the basic science behind antisense oligonucleotides chemistry, toxicology, manufacturing, to safety assessments, the design of therapeutic protocols, to clinical experience.
Antisense oligonucleotides are single strands of DNA or RNA that are complementary to a chosen sequence. While the idea of antisense oligonucleotides to target single genes dates back to the 1970's, most advances have taken place in recent years. The increasing number of antisense oligonucleotide programs in clinical development is a testament to the progress and understanding of pharmacologic, pharmacokinetic, and toxicologic properties as well as improvement in the delivery of oligonucleotides. This valuable book reviews the fundamentals of oligonucleotides, with a focus on antisense oligonucleotide drugs, and reports on the latest research underway worldwide.
* Helps readers understand antisense molecules and their targets, biochemistry, and toxicity mechanisms, roles in disease, and applications for safety and therapeutics
* Examines the principles, practices, and tools for scientists in both pre-clinical and clinical settings and how to apply them to antisense oligonucleotides
* Provides guidelines for scientists in drug design and discovery to help improve efficiency, assessment, and the success of drug candidates
* Includes interdisciplinary perspectives, from academia, industry, regulatory and from the fields of pharmacology, toxicology, biology, and medicinal chemistry
Oligonucleotide-Based Drugs and Therapeutics belongs on the reference shelves of chemists, pharmaceutical scientists, chemical biologists, toxicologists and other scientists working in the pharmaceutical and biotechnology industries. It will also be a valuable resource for regulatory specialists and safety assessment professionals and an important reference for academic researchers and post-graduates interested in therapeutics, antisense therapy, and oligonucleotides.
Nicolay Ferrari, PhD, is the Executive Director of the Canadian Critical Care Trials Group, a Canadian investigator-lead research network, Quebec, Canada. A former Director of Research in Pharmacology at Topigen Pharmaceuticals, Inc, over twenty years of research experience, Dr. Ferrari is the co-inventor of six patents.
Rosanne Seguin, PhD, is an Academic Associate at the Montreal Neurological Institute of McGill University, Montreal, Quebec, Canada. A former Director of Immunology and Development Support at Topigen Pharmaceuticals, Inc. Dr. Seguin has 20 years of research experience.
List of Contributors xvii
Preface xxi
Acknowledgments xxii
1 Mechanisms of Oligonucleotide Actions 1
Annemieke AartsmäRus, Aimee L. Jackson, and Arthur A. Levin
1.1 Introduction
1.2 Antisense Oligonucleotide Therapeutics 2
1.2.1 Antisense Activity Mediated by RNase H 2
1.2.2 The RNase H Mechanism 2
1.2.3 Chemical Modifications to Enhance RNase H¿mediated Antisense Activity 3
1.3 Oligonucleotides that Sterically Block Translation 5
1.4 Oligonucleotides that Act Through the RNAi Pathway 5
1.4.1 The RISC Pathway 5
1.4.2 Mechanisms of RISC¿mediated Gene Silencing 8
1.5 Chemical Modification of siRNAs and miRNAs 10
1.5.1 Delivery of Therapeutic siRNAs or miRNAs 12
1.6 Clinical Use of Oligonucleotides that Act through the RNAi Pathway 14
1.7 Oligonucleotides that Modulate Splicing 17
1.7.1 Pre¿mRNA Splicing and Disease 17
1.7.2 Mechanisms of Oligonucleotide¿mediated Splicing Modulation 17
1.7.3 Chemical Modifications that Enhance Activity of Oligonucleotidebased Splicing Modulators 21
1.7.4 Clinical Applications of Splicing Modulators 22
1.8 Conclusions 22
References 22
2 The Medicinal Chemistry of Antisense Oligonucleotides 39
Jonathan K. Watts
2.1 Introduction:The Antisense Approach and the Need for Chemical Modification 39
2.1.1 How Does Medicinal Chemistry Apply to Oligonucleotides? 40
2.1.2 Chemistry and Toxicity 41
2.2 Why Chemically Modify an Oligonucleotide? 42
2.2.1 Medicinal Chemistry Can Increase Nuclease Stability 42
2.2.2 Medicinal Chemistry Can Tune Binding Affinity and Specificity 43
2.2.3 Medicinal Chemistry Can Change Interactions with Cellular Factors 44
2.2.4 Medicinal Chemistry Can Modulate Immunostimulation 45
2.2.5 Medicinal Chemistry Can Improve RNase H Cleavage Specificity 46
2.2.6 Medicinal Chemistry Can Improve Cellular Uptake and Subcellular Trafficking 47
2.3 Chemical Modifications of Current Importance by Structural Class 48
2.3.1 Sugar Modifications 48
2.3.1.1 2¿¿Modified Ribose Sugars 48
2.3.1.2 2¿¿Modified Arabinose Sugars 50
2.3.1.3 2¿,4¿¿Difluorinated Nucleosides 50
2.3.1.4 Constrained Nucleotides 50
2.3.1.5 Sugars with Expanded Ring Size 53
2.3.2 Phosphate Modifications 54
2.3.2.1 Phosphorothioate 54
2.3.2.2 Other Charged Phosphate Analogues 58
2.3.2.3 Neutral Mimics of the Phosphate Linkage 58
2.3.2.4 Metabolically Stable 5¿¿Phosphate Analogues 60
2.3.3 Total Replacement of the Sugar¿Phosphate Backbone 61
2.3.4 Nucleobase Modifications 62
2.3.4.1 Sulfur¿Modified Nucleobases 63
2.3.4.2 5¿Modified Pyrimidines 63
2.3.4.3 Nucleobases with Expanded Hydrogen Bonding Networks 65
2.3.5 Assembly of Oligonucleotides into Multimeric Structures 66
2.4 Conclusion 67
References 69
3 Cellular Pharmacology of Antisense Oligonucleotides 91
Xin Ming
3.1 Introduction91
3.2 Molecular Mechanisms of Antisense Oligonucleotides 92
3.2.1 Classic Antisense Oligonucleotides 92
3.2.2 siRNA 94
3.2.3 Splice Switching Oligonucleotides 94
3.2.4 microRNA Antagomirs 95
3.2.5 lncRNAs Antagomirs 95
3.3 Cellular Pharmacology of Antisense Oligonucleotides 96
3.3.1 Endocytosis of Free Oligonucleotides 98
3.3.2 Endocytosis of Oligonucleotide Conjugates 98
3.3.3 Uptake and Trafficking of Oligonucleotides Incorporated into Nanocarriers 100
3.4 Conclusion 101
References 101
4 Pharmacokinetics and Pharmacodynamics of Antisense Oligonucleotides 107
Helen Lightfoot, Anneliese Schneider, and Jonathan Hall
4.1 Introduction 107
4.2 Pharmacokinetic Properties of Antisense Oligonucleotides 108
4.2.1 Protein Binding 109
4.2.2 Dose Dependency of ASO Pharmacokinetics 110
4.2.3 Absorption 110
4.2.4 Distribution 111
4.2.5 Metabolism and Excretion 112
4.3 Pharmacodynamic Properties of Antisense Oligonucleotides 113
4.3.1 ASO Target Selection and Validation 114
4.3.2 Mechanisms of Action 117
4.3.3 Biomarkers and PD Endpoints 118
4.4 PD and PK Results and Strategies of ASOs in Clinical Development 119
4.4.1 Genetic Diseases 122
4.4.1.1 Mipomersen, Apolipoprotein B¿100, and Hypercholesterolemia 122
4.4.1.2 Drisapersen, Dystrophin, and Duchenne Muscular Dystrophy (DMD) 123
4.4.2 Infectious Diseases 125
4.4.2.1 Miravirsen, miR¿122, and Hepatitis C Virus (HCV) 125
4.4.3 Cancer 126
4.4.3.1 Custirsen, Clusterin, and Cancer 126
4.4.3.2 LY2181308 (ISIS¿23722), Survivin, and Cancer 127
4.5 Summary and Conclusions 128
References 130
5 Tissue Distribution, Metabolism, and Clearance 137
Mehrdad Dirin and Johannes Winkler
5.1 Introduction137
5.2 Tissue Distribution 138
5.2.1 Dermal Delivery 138
5.2.2 Ocular Delivery 139
5.2.3 Oral Administration 139
5.2.4 Intrathecal Delivery 141
5.2.5 Intravesical Administration 142
5.2.6 Pulmonary Administration 142
5.2.7 Distribution to Muscular Tissue 143
5.2.8 Intravenous Administration 144
5.3 Cellular Uptake 146
5.4 Metabolism and Clearance 148
5.4.1 Phosphorothioates Including 2¿¿Modifications 148
5.4.2 Phosphorodiamidate Morpholino Oligonucleotides 149
5.5 Conclusion 150
References 151
6 Hybridization¿Independent Effects: Principles and Specific Considerations for Oligonucleotide Drugs 161
Nicolay Ferrari
6.1 Background 161
6.2 Mechanisms of Hybridization¿independent Toxicities 162
6.2.1 Effects Related to Oligonucleotide Sequence 162
6.2.1.1 Unmethylated CpG Motifs 162
6.2.1.2 Poly¿G Sequences 163
6.2.1.3 DNA Triplex¿forming Oligonucleotides 164
6.2.1.4 Other Motifs 164
6.2.2 Effects Related to Oligonucleotide Chemistry 164
6.2.2.1 Phosphorothioate Oligonucleotides 165
6.2.2.2 Effects of Other Chemical Modifications 171
6.3 Hybridization¿independent Effects Following Local Delivery of Oligonucleotides 171
6.3.1 Pulmonary Toxicity of Inhaled Oligonucleotides 171
6.3.1.1 Specific Considerations for Inhaled Oligonucleotides 173
6.3.2 Approaches to Reduce Hybridization¿independent Class Effects of Inhaled Oligonucleotides 175
6.3.2.1 Mixed Phosphorothioate/Phosphodiester Oligonucleotides 175
6.4 Conclusion 180
References 180
7 Hybridization¿Dependent Effects: The Prediction, Evaluation,and Consequences of Unintended Target Hybridization 191
Jeremy D. A. Kitson, Piotr J. Kamola, and Lauren Kane
7.1 Introduction 191
7.1.1 Scope of this Review: RNase H1¿dependent ASOs 192
7.2 Specificity Studies with ASOs 192
7.3 Implications of the Nuclear Site of Action of RNase H1 194
7.3.1 Confirmation of Unintended Targets within Introns 195
7.4 Mechanism of OTE 196
7.5 Determining the Extent that Accessibility, Affinity and, Mismatch Tolerance Contribute to Off¿target Activity 198
7.5.1 Accessibility 198
7.5.2 Affinity 199
7.5.3 The Interaction of RNase H1 with the RNA/ASO Duplex 200
7.5.4 Mismatch Tolerance 202
7.6 Consequences of Unintended Transcript Knockdown: In Vivo and In Vitro Toxicity 203
7.7 Identification and Evaluation of Putative OTEs 207
7.7.1 Computational Prediction of Unintended Targeting 207
7.7.1.1 Database Creation 209
7.7.1.2 Sequence Alignments 209
7.7.1.3 Cross¿species Off¿target Homology 210
7.7.1.4 Results Filtering and Annotation 211
7.7.1.5 RNA Structure and Target Accessibility 211
7.7.1.6 ASO-Target Duplex Thermodynamics 213
7.7.1.7 Computational Framework for OTEs 214
7.7.1.8 In Vitro Screening for OTEs 214
7.7.1.9 Methods for Measuring Gene Expression 216
7.8 Summary 216
Acknowledgments 217
References 218
8 Class¿Related Proinflammatory Effects 227
Rosanne Seguin
8.1 Introduction 227
8.2 Proinflammatory Effects of ASO for Consideration in Drug Development 228
8.2.1 Activation of the Complement Cascade in Monkeys 228
8.2.2 Cytokine Release 229
8.2.3 Mononuclear Cellular Infiltrate 232
8.2.4 Hematological Changes 236
8.2.5 Immunogenicity 237
8.3 Conclusions 238
References 239
9 Exaggerated Pharmacology 243
Alain Guimond and Doug Kornbrust
9.1 Introduction 243
9.2 Regulatory Expectations 244
9.3 Scope of EP Assessment 245
9.3.1 Species Selection 245
9.3.2 Determination of Pharmacologic Relevance 247
9.4 EP Evaluation Strategies 248
9.4.1 Concerns About the Use of Animal¿active Analogues 248
9.4.2 Animal¿active Analogues in Reproductive and/or Carcinogenicity Studies 250
9.4.3 Other Considerations for Use of Animal Analogues 250
9.4.4 The Use of Inactive Analogues as Control Articles 250
9.4.5 The Role of Formulations 251
9.4.6 Aptamer Oligonucleotides 251
9.4.7 Immunostimulatory Oligonucleotides 252
9.4.8 MicroRNA 253
9.5 Conclusions 254
References 255
10 Genotoxicity Tests for Novel Oligonucleotide¿Based Therapeutics 257
Cindy L. Berman, Scott A. Barros, Sheila M. Galloway, Peter Kasper, Frederick B. Oleson, Catherine C. Priestley, Kevin S. Sweder, Michael J. Schlosser, and Zhanna Sobol
10.1 Introduction 257
10.1.1...
| Erscheinungsjahr: | 2018 |
|---|---|
| Fachbereich: | Allgemeines |
| Genre: | Chemie |
| Rubrik: | Naturwissenschaften & Technik |
| Medium: | Buch |
| Inhalt: | 576 S. |
| ISBN-13: | 9781118537336 |
| ISBN-10: | 1118537335 |
| Sprache: | Englisch |
| Einband: | Gebunden |
| Redaktion: |
Ferrari, Nicolay
Seguin, Rosanne |
| Herausgeber: | Nicolay Ferrari/Rosanne Seguin |
| Hersteller: | Wiley |
| Maße: | 235 x 157 x 35 mm |
| Von/Mit: | Nicolay Ferrari (u. a.) |
| Erscheinungsdatum: | 31.07.2018 |
| Gewicht: | 0,976 kg |
Nicolay Ferrari, PhD, is the Executive Director of the Canadian Critical Care Trials Group, a Canadian investigator-lead research network, Quebec, Canada. A former Director of Research in Pharmacology at Topigen Pharmaceuticals, Inc, over twenty years of research experience, Dr. Ferrari is the co-inventor of six patents.
Rosanne Seguin, PhD, is an Academic Associate at the Montreal Neurological Institute of McGill University, Montreal, Quebec, Canada. A former Director of Immunology and Development Support at Topigen Pharmaceuticals, Inc. Dr. Seguin has 20 years of research experience.
List of Contributors xvii
Preface xxi
Acknowledgments xxii
1 Mechanisms of Oligonucleotide Actions 1
Annemieke AartsmäRus, Aimee L. Jackson, and Arthur A. Levin
1.1 Introduction
1.2 Antisense Oligonucleotide Therapeutics 2
1.2.1 Antisense Activity Mediated by RNase H 2
1.2.2 The RNase H Mechanism 2
1.2.3 Chemical Modifications to Enhance RNase H¿mediated Antisense Activity 3
1.3 Oligonucleotides that Sterically Block Translation 5
1.4 Oligonucleotides that Act Through the RNAi Pathway 5
1.4.1 The RISC Pathway 5
1.4.2 Mechanisms of RISC¿mediated Gene Silencing 8
1.5 Chemical Modification of siRNAs and miRNAs 10
1.5.1 Delivery of Therapeutic siRNAs or miRNAs 12
1.6 Clinical Use of Oligonucleotides that Act through the RNAi Pathway 14
1.7 Oligonucleotides that Modulate Splicing 17
1.7.1 Pre¿mRNA Splicing and Disease 17
1.7.2 Mechanisms of Oligonucleotide¿mediated Splicing Modulation 17
1.7.3 Chemical Modifications that Enhance Activity of Oligonucleotidebased Splicing Modulators 21
1.7.4 Clinical Applications of Splicing Modulators 22
1.8 Conclusions 22
References 22
2 The Medicinal Chemistry of Antisense Oligonucleotides 39
Jonathan K. Watts
2.1 Introduction:The Antisense Approach and the Need for Chemical Modification 39
2.1.1 How Does Medicinal Chemistry Apply to Oligonucleotides? 40
2.1.2 Chemistry and Toxicity 41
2.2 Why Chemically Modify an Oligonucleotide? 42
2.2.1 Medicinal Chemistry Can Increase Nuclease Stability 42
2.2.2 Medicinal Chemistry Can Tune Binding Affinity and Specificity 43
2.2.3 Medicinal Chemistry Can Change Interactions with Cellular Factors 44
2.2.4 Medicinal Chemistry Can Modulate Immunostimulation 45
2.2.5 Medicinal Chemistry Can Improve RNase H Cleavage Specificity 46
2.2.6 Medicinal Chemistry Can Improve Cellular Uptake and Subcellular Trafficking 47
2.3 Chemical Modifications of Current Importance by Structural Class 48
2.3.1 Sugar Modifications 48
2.3.1.1 2¿¿Modified Ribose Sugars 48
2.3.1.2 2¿¿Modified Arabinose Sugars 50
2.3.1.3 2¿,4¿¿Difluorinated Nucleosides 50
2.3.1.4 Constrained Nucleotides 50
2.3.1.5 Sugars with Expanded Ring Size 53
2.3.2 Phosphate Modifications 54
2.3.2.1 Phosphorothioate 54
2.3.2.2 Other Charged Phosphate Analogues 58
2.3.2.3 Neutral Mimics of the Phosphate Linkage 58
2.3.2.4 Metabolically Stable 5¿¿Phosphate Analogues 60
2.3.3 Total Replacement of the Sugar¿Phosphate Backbone 61
2.3.4 Nucleobase Modifications 62
2.3.4.1 Sulfur¿Modified Nucleobases 63
2.3.4.2 5¿Modified Pyrimidines 63
2.3.4.3 Nucleobases with Expanded Hydrogen Bonding Networks 65
2.3.5 Assembly of Oligonucleotides into Multimeric Structures 66
2.4 Conclusion 67
References 69
3 Cellular Pharmacology of Antisense Oligonucleotides 91
Xin Ming
3.1 Introduction91
3.2 Molecular Mechanisms of Antisense Oligonucleotides 92
3.2.1 Classic Antisense Oligonucleotides 92
3.2.2 siRNA 94
3.2.3 Splice Switching Oligonucleotides 94
3.2.4 microRNA Antagomirs 95
3.2.5 lncRNAs Antagomirs 95
3.3 Cellular Pharmacology of Antisense Oligonucleotides 96
3.3.1 Endocytosis of Free Oligonucleotides 98
3.3.2 Endocytosis of Oligonucleotide Conjugates 98
3.3.3 Uptake and Trafficking of Oligonucleotides Incorporated into Nanocarriers 100
3.4 Conclusion 101
References 101
4 Pharmacokinetics and Pharmacodynamics of Antisense Oligonucleotides 107
Helen Lightfoot, Anneliese Schneider, and Jonathan Hall
4.1 Introduction 107
4.2 Pharmacokinetic Properties of Antisense Oligonucleotides 108
4.2.1 Protein Binding 109
4.2.2 Dose Dependency of ASO Pharmacokinetics 110
4.2.3 Absorption 110
4.2.4 Distribution 111
4.2.5 Metabolism and Excretion 112
4.3 Pharmacodynamic Properties of Antisense Oligonucleotides 113
4.3.1 ASO Target Selection and Validation 114
4.3.2 Mechanisms of Action 117
4.3.3 Biomarkers and PD Endpoints 118
4.4 PD and PK Results and Strategies of ASOs in Clinical Development 119
4.4.1 Genetic Diseases 122
4.4.1.1 Mipomersen, Apolipoprotein B¿100, and Hypercholesterolemia 122
4.4.1.2 Drisapersen, Dystrophin, and Duchenne Muscular Dystrophy (DMD) 123
4.4.2 Infectious Diseases 125
4.4.2.1 Miravirsen, miR¿122, and Hepatitis C Virus (HCV) 125
4.4.3 Cancer 126
4.4.3.1 Custirsen, Clusterin, and Cancer 126
4.4.3.2 LY2181308 (ISIS¿23722), Survivin, and Cancer 127
4.5 Summary and Conclusions 128
References 130
5 Tissue Distribution, Metabolism, and Clearance 137
Mehrdad Dirin and Johannes Winkler
5.1 Introduction137
5.2 Tissue Distribution 138
5.2.1 Dermal Delivery 138
5.2.2 Ocular Delivery 139
5.2.3 Oral Administration 139
5.2.4 Intrathecal Delivery 141
5.2.5 Intravesical Administration 142
5.2.6 Pulmonary Administration 142
5.2.7 Distribution to Muscular Tissue 143
5.2.8 Intravenous Administration 144
5.3 Cellular Uptake 146
5.4 Metabolism and Clearance 148
5.4.1 Phosphorothioates Including 2¿¿Modifications 148
5.4.2 Phosphorodiamidate Morpholino Oligonucleotides 149
5.5 Conclusion 150
References 151
6 Hybridization¿Independent Effects: Principles and Specific Considerations for Oligonucleotide Drugs 161
Nicolay Ferrari
6.1 Background 161
6.2 Mechanisms of Hybridization¿independent Toxicities 162
6.2.1 Effects Related to Oligonucleotide Sequence 162
6.2.1.1 Unmethylated CpG Motifs 162
6.2.1.2 Poly¿G Sequences 163
6.2.1.3 DNA Triplex¿forming Oligonucleotides 164
6.2.1.4 Other Motifs 164
6.2.2 Effects Related to Oligonucleotide Chemistry 164
6.2.2.1 Phosphorothioate Oligonucleotides 165
6.2.2.2 Effects of Other Chemical Modifications 171
6.3 Hybridization¿independent Effects Following Local Delivery of Oligonucleotides 171
6.3.1 Pulmonary Toxicity of Inhaled Oligonucleotides 171
6.3.1.1 Specific Considerations for Inhaled Oligonucleotides 173
6.3.2 Approaches to Reduce Hybridization¿independent Class Effects of Inhaled Oligonucleotides 175
6.3.2.1 Mixed Phosphorothioate/Phosphodiester Oligonucleotides 175
6.4 Conclusion 180
References 180
7 Hybridization¿Dependent Effects: The Prediction, Evaluation,and Consequences of Unintended Target Hybridization 191
Jeremy D. A. Kitson, Piotr J. Kamola, and Lauren Kane
7.1 Introduction 191
7.1.1 Scope of this Review: RNase H1¿dependent ASOs 192
7.2 Specificity Studies with ASOs 192
7.3 Implications of the Nuclear Site of Action of RNase H1 194
7.3.1 Confirmation of Unintended Targets within Introns 195
7.4 Mechanism of OTE 196
7.5 Determining the Extent that Accessibility, Affinity and, Mismatch Tolerance Contribute to Off¿target Activity 198
7.5.1 Accessibility 198
7.5.2 Affinity 199
7.5.3 The Interaction of RNase H1 with the RNA/ASO Duplex 200
7.5.4 Mismatch Tolerance 202
7.6 Consequences of Unintended Transcript Knockdown: In Vivo and In Vitro Toxicity 203
7.7 Identification and Evaluation of Putative OTEs 207
7.7.1 Computational Prediction of Unintended Targeting 207
7.7.1.1 Database Creation 209
7.7.1.2 Sequence Alignments 209
7.7.1.3 Cross¿species Off¿target Homology 210
7.7.1.4 Results Filtering and Annotation 211
7.7.1.5 RNA Structure and Target Accessibility 211
7.7.1.6 ASO-Target Duplex Thermodynamics 213
7.7.1.7 Computational Framework for OTEs 214
7.7.1.8 In Vitro Screening for OTEs 214
7.7.1.9 Methods for Measuring Gene Expression 216
7.8 Summary 216
Acknowledgments 217
References 218
8 Class¿Related Proinflammatory Effects 227
Rosanne Seguin
8.1 Introduction 227
8.2 Proinflammatory Effects of ASO for Consideration in Drug Development 228
8.2.1 Activation of the Complement Cascade in Monkeys 228
8.2.2 Cytokine Release 229
8.2.3 Mononuclear Cellular Infiltrate 232
8.2.4 Hematological Changes 236
8.2.5 Immunogenicity 237
8.3 Conclusions 238
References 239
9 Exaggerated Pharmacology 243
Alain Guimond and Doug Kornbrust
9.1 Introduction 243
9.2 Regulatory Expectations 244
9.3 Scope of EP Assessment 245
9.3.1 Species Selection 245
9.3.2 Determination of Pharmacologic Relevance 247
9.4 EP Evaluation Strategies 248
9.4.1 Concerns About the Use of Animal¿active Analogues 248
9.4.2 Animal¿active Analogues in Reproductive and/or Carcinogenicity Studies 250
9.4.3 Other Considerations for Use of Animal Analogues 250
9.4.4 The Use of Inactive Analogues as Control Articles 250
9.4.5 The Role of Formulations 251
9.4.6 Aptamer Oligonucleotides 251
9.4.7 Immunostimulatory Oligonucleotides 252
9.4.8 MicroRNA 253
9.5 Conclusions 254
References 255
10 Genotoxicity Tests for Novel Oligonucleotide¿Based Therapeutics 257
Cindy L. Berman, Scott A. Barros, Sheila M. Galloway, Peter Kasper, Frederick B. Oleson, Catherine C. Priestley, Kevin S. Sweder, Michael J. Schlosser, and Zhanna Sobol
10.1 Introduction 257
10.1.1...
| Erscheinungsjahr: | 2018 |
|---|---|
| Fachbereich: | Allgemeines |
| Genre: | Chemie |
| Rubrik: | Naturwissenschaften & Technik |
| Medium: | Buch |
| Inhalt: | 576 S. |
| ISBN-13: | 9781118537336 |
| ISBN-10: | 1118537335 |
| Sprache: | Englisch |
| Einband: | Gebunden |
| Redaktion: |
Ferrari, Nicolay
Seguin, Rosanne |
| Herausgeber: | Nicolay Ferrari/Rosanne Seguin |
| Hersteller: | Wiley |
| Maße: | 235 x 157 x 35 mm |
| Von/Mit: | Nicolay Ferrari (u. a.) |
| Erscheinungsdatum: | 31.07.2018 |
| Gewicht: | 0,976 kg |
Ähnliche Produkte
Aktuell nicht verfügbar
Aktuell nicht verfügbar
Aktuell nicht verfügbar
Aktuell nicht verfügbar
Aktuell nicht verfügbar
Aktuell nicht verfügbar
Aktuell nicht verfügbar